IMPACTS
The main expected outcome of the MPX-RESPONSE project is to allow the European Union and the international community to respond to public health emergencies of international scale, and in particular to the potential threat of re-emergence of the mpox epidemic.
Specific results expected
Assess the efficacy and safety of Tecovirimat SIGA for treating mpox virus disease, as well as assess other potential therapeutic candidates as they emerge.
Implement an innovative approach, known as platform trials, for conducting clinical trial in response to public health emergencies.
Establish an international cooperation model to prevent and manage communicable disease epidemics.
Formulate recommendations to shape public health policies and to facilitate future clinical management of epidemics.
Impacts
Scientific
impacts
- Better understanding the clinical and virological course of mpox, with and without antiviral treatment.
- Produce high quality data on the appropriate management of mpox patients
- Demonstrate therapeutic impact of antiviral drugs
Economic
impacts
- Reduction of public health costs
- Enhanced coordination of clinical trials to maximize patient inclusion for high- powered studies, at reasonable costs and speed-
- optimize resource efficiency in the scientific response to health emergencies, achieving greater results with reduced expenditure
Societal
impacts
- Higher community awareness and access to early treatment
- Reduction of morbidity, disease prevalence and transmission
- International framework for infectious disease trials
- Support research capacities beyond Europe
Useful links
For comprehensive details regarding mpox, including its transmission dynamics, symptoms and available treatments please visit the following informative pages:
